Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple sclerosis -- Research -- Planning -- Congresses. --- Demyelinating Autoimmune Diseases, CNS --- Science --- Autoimmune Diseases of the Nervous System --- Demyelinating Diseases --- Natural Science Disciplines --- Autoimmune Diseases --- Disciplines and Occupations --- Nervous System Diseases --- Immune System Diseases --- Diseases --- Multiple Sclerosis --- Research --- Medicine --- Health & Biological Sciences --- Neurology --- Multiple sclerosis --- Planning --- MS (Disease) --- Sclerosis, Multiple --- Demyelination --- Myelin sheath --- Virus diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

From 1910 to 1919, New Orleans suffered at the hands of its very own Jack the Ripper–style killer. The story has been the subject of websites, short stories, novels, a graphic novel, and most recently the FX television series American Horror Story . But the full story of gruesome murders, sympathetic victims, accused innocents, public panic, the New Orleans Mafia, and a mysterious killer has never been written. Until now. The Axeman repeatedly broke into the homes of Italian grocers in the dead of night, leaving his victims in a pool of blood. Iorlando Jordano, an innocent Italian grocer, and his teenaged son Frank were wrongly accused of one of those murders; corrupt officials convicted them with coerced testimony. Miriam C. Davis here expertly tells the story of the search for the Axeman and of the eventual exoneration of the innocent Jordanos. She proves that the person mostly widely suspected of being the Axeman was not the killer. She also shows what few have suspected—that the Axeman continued killing after leaving New Orleans in 1919. Only thirty years after Jack the Ripper stalked the streets of Whitechapel, the Axeman of New Orleans held an American city hostage. This book tells that story.

Serial murders --- Serial murder investigation

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Emergency management --- Disaster medicine --- Emergency medical services --- Integrated delivery of health care --- Planning --- United States.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description.

Suicide --- Suicidal behavior --- Clinical health psychology --- Clinical trials --- Nervous system --- Psychiatry and Psychology --- Publication Formats --- North America --- Evaluation Studies as Topic --- Self-Injurious Behavior --- Social Problems --- Epidemiologic Study Characteristics as Topic --- Health Care Evaluation Mechanisms --- Publication Characteristics --- Behavioral Symptoms --- Investigative Techniques --- Epidemiologic Methods --- Sociology --- Americas --- Public Health --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Behavior --- Social Sciences --- Geographic Locations --- Quality of Health Care --- Health Care Quality, Access, and Evaluation --- Environment and Public Health --- Anthropology, Education, Sociology and Social Phenomena --- Behavior and Behavior Mechanisms --- Geographicals --- Health Care --- Mental Disorders --- Clinical Trials as Topic --- Congresses --- United States --- Psychiatry --- Health & Biological Sciences --- Psychiatric Disorders, Individual --- Prevention --- Risk factors. --- Prevention.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"Neurodegeneration: Exploring Commonalities Across Diseases is the summary of a workshop hosted by the Institute of Medicine's (IOM's) Forum on Neuroscience and Nervous System Disorders in Spring 2012 to explore commonalities across neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Participants from academia; pharmaceutical and biotechnology industries; government agencies such as the National Institutes of Health and the U.S. Department of Veterans Affairs (VA); patient advocacy groups; and private foundations presented and identified potential opportunities for collaboration across the respective research and development communities. This report identifies and discusses commonalities related to genetic and cellular mechanisms, identifies areas of fundamental science needed to facilitate therapeutics development, and explores areas of potential collaboration among the respective research communities. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, ALS, and FTD, are becoming increasingly prevalent in the United States due to an aging population. Implications are grave for quality of life and health care costs. Research on neurodegenerative diseases has expanded greatly over the past four decades. Nevertheless, fundamental questions remain about the biology of these diseases, and further insights into the mechanisms of these diseases would help to inform the development of effective means to prevent and to efficiently treat them. Recent findings have revealed certain commonalities in genetic and cellular mechanisms across neurodegenerative diseases. These findings suggest that it might be valuable - at least in some cases - to change the traditional way of studying these diseases by no longer seeing each as an independent entity, but rather as clinical variants of common cellular and molecular biological defects. This approach could help enhance basic scientific understanding of neurodegenerative disease, and could help with the development of biomarkers and new therapeutics."

Biology -- Research -- Congresses. --- Nervous system -- Degeneration -- Congresses. --- Nervous system --- Biology --- Research --- Methods --- Publication Formats --- Nervous System Diseases --- Diseases --- Science --- Publication Characteristics --- Investigative Techniques --- Natural Science Disciplines --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Disciplines and Occupations --- Congresses --- Biomedical Research --- Research Design --- Neurodegenerative Diseases --- Health & Biological Sciences --- Biomedical Engineering --- Degeneration